EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY

Their core work

EULAR is the pan-European professional umbrella body for rheumatology, representing national societies of rheumatology, patient associations, and scientific bodies across Europe. Their primary function is setting clinical standards, publishing treatment recommendations, and organizing the largest annual European rheumatology congress — giving them unparalleled reach into the clinical rheumatology community. In research consortia, they contribute this network as infrastructure: access to patient populations, coordination with clinical sites across member countries, and the legitimacy to drive guideline-level adoption of research outputs. Their participation in H2020 projects reflects a role as a bridge between clinical research findings and real-world implementation across European rheumatology practice.

What they specialise in

How they've shifted over time

In their earliest H2020 project (2017–2020), EULAR's engagement centered on a specific rare autoimmune condition — Sjögren syndrome — with a methodological focus on cohort harmonization and big data integration across research registries. By the 2021–2026 period, the focus shifted to more prevalent inflammatory diseases (psoriatic arthritis, psoriasis) with a stronger emphasis on clinical utility: predictive models, treatment response, early diagnosis, and patient involvement. This trajectory suggests EULAR is moving from data-infrastructure projects toward precision medicine and patient-centered outcomes, areas where their European-scale clinical community creates direct translational value.

EULAR is increasingly positioning itself as a consortium partner that can validate AI-driven clinical tools and predictive models at European scale, particularly in chronic inflammatory diseases with heterogeneous patient populations.

How they like to work

EULAR joins as a participant, never a project coordinator — consistent with an organization whose value lies in network access and community reach rather than research execution. Both projects are large RIA consortia (HIPPOCRATES spans 63 partners across 15 countries), indicating comfort operating within complex multi-stakeholder structures. Their contribution is likely standardized: patient engagement frameworks, dissemination to rheumatology societies, and bridging research outputs toward clinical guideline adoption.

EULAR has collaborated with 63 unique partners across 15 countries within just two projects, reflecting the large consortium structures typical of H2020 health research. Their network is pan-European by design, spanning their member societies across Western, Central, and Southern Europe.

What sets them apart

EULAR is the only organization in Europe that can claim to represent rheumatology as a field — not a single hospital, not a single country, but the entire professional and patient community. For any consortium researching rheumatic or musculoskeletal diseases, EULAR's participation is a signal of clinical legitimacy and a direct pathway to adoption by practicing rheumatologists across 45+ member countries. No other partner can offer simultaneous access to national rheumatology societies, patient organizations, and a congress attended by over 14,000 clinicians annually.

Highlights from their portfolio

• HIPPOCRATES
  The largest and most recent engagement (2021–2026), addressing psoriatic arthritis across multiple European states with a focus on predictive models and early diagnosis — EULAR's longest active H2020 commitment.
• HarmonicSS
  Rare-disease cohort harmonization for Sjögren syndrome combining big data analytics with multi-country clinical registries — an early signal of EULAR's value in cross-border data infrastructure projects.